|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FZD3 |
Gene summary for FZD3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FZD3 | Gene ID | 7976 |
| Gene name | frizzled class receptor 3 | |
| Gene Alias | Fz-3 | |
| Cytomap | 8p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q9NPG1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7976 | FZD3 | HCC1_Meng | Human | Liver | HCC | 5.27e-06 | -2.71e-02 | 0.0246 |
| 7976 | FZD3 | HCC1 | Human | Liver | HCC | 1.84e-08 | 2.41e+00 | 0.5336 |
| 7976 | FZD3 | HCC2 | Human | Liver | HCC | 5.99e-18 | 2.23e+00 | 0.5341 |
| 7976 | FZD3 | HCC5 | Human | Liver | HCC | 5.71e-11 | 2.23e+00 | 0.4932 |
| 7976 | FZD3 | S028 | Human | Liver | HCC | 2.57e-04 | 2.78e-01 | 0.2503 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000734611 | Liver | HCC | regulation of mitotic cell cycle | 255/7958 | 457/18723 | 4.96e-09 | 1.30e-07 | 255 |
| GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
| GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
| GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
| GO:0045786 | Liver | HCC | negative regulation of cell cycle | 204/7958 | 385/18723 | 1.84e-05 | 1.99e-04 | 204 |
| GO:0045930 | Liver | HCC | negative regulation of mitotic cell cycle | 130/7958 | 235/18723 | 4.69e-05 | 4.50e-04 | 130 |
| GO:006007021 | Liver | HCC | canonical Wnt signaling pathway | 162/7958 | 303/18723 | 7.00e-05 | 6.32e-04 | 162 |
| GO:00018415 | Liver | HCC | neural tube formation | 62/7958 | 102/18723 | 1.47e-04 | 1.18e-03 | 62 |
| GO:001072011 | Liver | HCC | positive regulation of cell development | 155/7958 | 298/18723 | 5.39e-04 | 3.48e-03 | 155 |
| GO:00018433 | Liver | HCC | neural tube closure | 53/7958 | 88/18723 | 5.95e-04 | 3.75e-03 | 53 |
| GO:003090121 | Liver | HCC | midbrain development | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
| GO:00140204 | Liver | HCC | primary neural tube formation | 56/7958 | 94/18723 | 6.19e-04 | 3.86e-03 | 56 |
| GO:00606063 | Liver | HCC | tube closure | 53/7958 | 89/18723 | 8.67e-04 | 5.14e-03 | 53 |
| GO:00219154 | Liver | HCC | neural tube development | 82/7958 | 152/18723 | 2.83e-03 | 1.33e-02 | 82 |
| GO:00507674 | Liver | HCC | regulation of neurogenesis | 181/7958 | 364/18723 | 3.00e-03 | 1.40e-02 | 181 |
| GO:00507693 | Liver | HCC | positive regulation of neurogenesis | 116/7958 | 225/18723 | 3.67e-03 | 1.63e-02 | 116 |
| GO:00018384 | Liver | HCC | embryonic epithelial tube formation | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
| GO:0097194 | Liver | HCC | execution phase of apoptosis | 48/7958 | 85/18723 | 6.47e-03 | 2.63e-02 | 48 |
| GO:00721754 | Liver | HCC | epithelial tube formation | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
| GO:1900117 | Liver | HCC | regulation of execution phase of apoptosis | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501022 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
| hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa0520521 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
| hsa0501032 | Liver | HCC | Alzheimer disease | 254/4020 | 384/8465 | 3.75e-14 | 8.97e-13 | 4.99e-13 | 254 |
| hsa0502232 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
| hsa0522511 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa051653 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa0520531 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| WNT5B | FZD3 | WNT5B_FZD3 | ncWNT | CRC | MSI-H |
| WNT5A | FZD3 | WNT5A_FZD3 | ncWNT | Esophagus | ESCC |
| WNT5B | FZD3 | WNT5B_FZD3 | ncWNT | Esophagus | ESCC |
| WNT10A | FZD3_LRP6 | WNT10A_FZD3_LRP6 | WNT | Esophagus | ESCC |
| WNT10B | FZD3_LRP6 | WNT10B_FZD3_LRP6 | WNT | Esophagus | ESCC |
| WNT2 | FZD3_LRP6 | WNT2_FZD3_LRP6 | WNT | Esophagus | ESCC |
| WNT2B | FZD3_LRP6 | WNT2B_FZD3_LRP6 | WNT | Esophagus | ESCC |
| WNT3A | FZD3_LRP6 | WNT3A_FZD3_LRP6 | WNT | Esophagus | ESCC |
| WNT7B | FZD3_LRP6 | WNT7B_FZD3_LRP6 | WNT | Esophagus | ESCC |
| WNT9A | FZD3_LRP6 | WNT9A_FZD3_LRP6 | WNT | Esophagus | ESCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FZD3 | SNV | Missense_Mutation | c.1409C>T | p.Thr470Ile | p.T470I | Q9NPG1 | protein_coding | tolerated(0.15) | benign(0.433) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| FZD3 | SNV | Missense_Mutation | c.1606N>A | p.Leu536Ile | p.L536I | Q9NPG1 | protein_coding | tolerated(0.18) | possibly_damaging(0.632) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FZD3 | SNV | Missense_Mutation | c.794N>G | p.Asn265Ser | p.N265S | Q9NPG1 | protein_coding | deleterious(0.02) | possibly_damaging(0.837) | TCGA-BH-A0H3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FZD3 | SNV | Missense_Mutation | c.1057N>A | p.Glu353Lys | p.E353K | Q9NPG1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FZD3 | deletion | Frame_Shift_Del | novel | c.1546delN | p.Glu518ArgfsTer2 | p.E518Rfs*2 | Q9NPG1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FZD3 | SNV | Missense_Mutation | novel | c.221C>T | p.Ser74Phe | p.S74F | Q9NPG1 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FZD3 | SNV | Missense_Mutation | rs200012243 | c.547N>T | p.Arg183Cys | p.R183C | Q9NPG1 | protein_coding | deleterious(0.01) | possibly_damaging(0.676) | TCGA-VS-A9UR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| FZD3 | SNV | Missense_Mutation | novel | c.1777C>T | p.Arg593Cys | p.R593C | Q9NPG1 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-5M-AATE-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| FZD3 | SNV | Missense_Mutation | rs372290611 | c.1099N>A | p.Asp367Asn | p.D367N | Q9NPG1 | protein_coding | tolerated(0.39) | benign(0.341) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FZD3 | SNV | Missense_Mutation | novel | c.510N>C | p.Lys170Asn | p.K170N | Q9NPG1 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |